User:Mr. Ibrahem/Gadopiclenol
Jump to navigation
Jump to search
 | |
| Clinical data | |
|---|---|
| Trade names | Elucirem |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Gadolinium complex[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | None[1] |
| Excretion | Kidneys[1] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C35H54GdN7O15 |
| Molar mass | 970.10 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Gadopiclenol, sold under the brand name Elucirem, is a contrast agent used in magnetic resonance imaging (MRI) to detect lesions with abnormal blood vessels.[1] It may be used in those who are at least two years old.[1] It is given by injection into a vein.[1]
Common side effects include pain at the site of injection, headache, nausea, and dizziness.[1] Other side effects may include nephrogenic systemic fibrosis, allergic reactions, and retention of gadolinium.[1] Safety in pregnancy is unclear.[1] It is a paramagnetic macrocyclic non-ionic complex of gadolinium.[1]
Gadopiclenol was approved for medical use in the United States in 2022.[1] As of 2022 it is being looked at the approval agency in Europe.[3]
References
[edit]- ^ a b c d e f g h i j k l m n o "Elucirem- gadopiclenol injection". DailyMed. 12 October 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
- ^ "Drug Approval Package: Elucirem". U.S. Food and Drug Administration (FDA). 20 October 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022.
- ^ "FDA Approves Gadopiclenol for Contrast-Enhanced Magnetic Resonance Imaging". Pharmacy Times. Archived from the original on 27 September 2022. Retrieved 16 December 2022.